APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oncology & Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oncology & Cancer Drugs Market Outlook and Growth Opportunities 2026

Report ID 174018890421 December 2025191 pages

Choose your research edition.

Industry ResearchOncology & Cancer Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology & Cancer Drugs Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Oncology & Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology & Cancer Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology & Cancer Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Oncology & Cancer Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oncology & Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oncology & Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oncology & Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oncology & Cancer Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oncology & Cancer Drugs market include Sanofi, Novartis, Roche, Lunan, Eli Lilly and Company, GuiZhou YiBai, AstraZeneca, QILU and LUYE, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oncology & Cancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oncology & Cancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncology & Cancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oncology & Cancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Oncology & Cancer Drugs Segment by Company

Sanofi

Novartis

Roche

Lunan

Eli Lilly and Company

GuiZhou YiBai

AstraZeneca

QILU

LUYE

HENGRUI

HANSOH

Oncology & Cancer Drugs Segment by Type

Platinum-based drugs

Hormone

Antimetabolite

Alkaloid drugs

Targeted drug

Other

Oncology & Cancer Drugs Segment by Application

Blood Cancer

Gastrointestinal Cancer

Breast Cancer

Prostate Cancer

Respiratory/Lung Cancer

Other

Oncology & Cancer Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oncology & Cancer Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Oncology & Cancer Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oncology & Cancer Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Oncology & Cancer Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology & Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology & Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology & Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oncology & Cancer Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncology & Cancer Drugs industry.

Chapter 3: Detailed analysis of Oncology & Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Oncology & Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Oncology & Cancer Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oncology & Cancer Drugs Industry Trends Table 2. Oncology & Cancer Drugs Industry Drivers Table 3. Oncology & Cancer Drugs Industry Opportunities and Challenges Table 4. Oncology & Cancer Drugs Industry Restraints Table 5. Global Oncology & Cancer Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oncology & Cancer Drugs Revenue Share by Company (2021-2026) Table 7. Global Oncology & Cancer Drugs Sales Volume by Company (k tons) & (2021-2026) Table 8. Global Oncology & Cancer Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Oncology & Cancer Drugs Average Price (US$/ton) of Company (2021-2026) Table 10. Global Oncology & Cancer Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Oncology & Cancer Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Oncology & Cancer Drugs Company, Product Type & Application Table 13. Global Oncology & Cancer Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Oncology & Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Platinum-based drugs Table 18. Significant Companies of Hormone Table 19. Significant Companies of Antimetabolite Table 20. Significant Companies of Alkaloid drugs Table 21. Significant Companies of Targeted drug Table 22. Significant Companies of Other Table 23. Global Oncology & Cancer Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 24. Global Oncology & Cancer Drugs Sales Volume by Type (2021-2026) & (k tons) Table 25. Global Oncology & Cancer Drugs Sales Volume by Type (2027-2032) & (k tons) Table 26. Global Oncology & Cancer Drugs Sales Volume Share by Type (2021-2026) Table 27. Global Oncology & Cancer Drugs Sales Volume Share by Type (2027-2032) Table 28. Global Oncology & Cancer Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Oncology & Cancer Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Oncology & Cancer Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Oncology & Cancer Drugs Sales Value Share by Type (2021-2026) Table 32. Global Oncology & Cancer Drugs Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Blood Cancer Table 34. Significant Companies of Gastrointestinal Cancer Table 35. Significant Companies of Breast Cancer Table 36. Significant Companies of Prostate Cancer Table 37. Significant Companies of Respiratory/Lung Cancer Table 38. Significant Companies of Other Table 39. Global Oncology & Cancer Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 40. Global Oncology & Cancer Drugs Sales Volume by Application (2021-2026) & (k tons) Table 41. Global Oncology & Cancer Drugs Sales Volume by Application (2027-2032) & (k tons) Table 42. Global Oncology & Cancer Drugs Sales Volume Share by Application (2021-2026) Table 43. Global Oncology & Cancer Drugs Sales Volume Share by Application (2027-2032) Table 44. Global Oncology & Cancer Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Oncology & Cancer Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 46. Global Oncology & Cancer Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 47. Global Oncology & Cancer Drugs Sales Value Share by Application (2021-2026) Table 48. Global Oncology & Cancer Drugs Sales Value Share by Application (2027-2032) Table 49. Global Oncology & Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 50. Global Oncology & Cancer Drugs Sales by Region (2021-2026) & (k tons) Table 51. Global Oncology & Cancer Drugs Sales Market Share by Region (2021-2026) Table 52. Global Oncology & Cancer Drugs Sales by Region (2027-2032) & (k tons) Table 53. Global Oncology & Cancer Drugs Sales Market Share by Region (2027-2032) Table 54. Global Oncology & Cancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Oncology & Cancer Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 56. Global Oncology & Cancer Drugs Sales Value Share by Region (2021-2026) Table 57. Global Oncology & Cancer Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 58. Global Oncology & Cancer Drugs Sales Value Share by Region (2027-2032) Table 59. Global Oncology & Cancer Drugs Market Average Price (US$/ton) by Region (2021-2026) Table 60. Global Oncology & Cancer Drugs Market Average Price (US$/ton) by Region (2027-2032) Table 61. Global Oncology & Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 62. Global Oncology & Cancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Oncology & Cancer Drugs Sales by Country (2021-2026) & (k tons) Table 64. Global Oncology & Cancer Drugs Sales Market Share by Country (2021-2026) Table 65. Global Oncology & Cancer Drugs Sales by Country (2027-2032) & (k tons) Table 66. Global Oncology & Cancer Drugs Sales Market Share by Country (2027-2032) Table 67. Global Oncology & Cancer Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 68. Global Oncology & Cancer Drugs Sales Value Market Share by Country (2021-2026) Table 69. Global Oncology & Cancer Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 70. Global Oncology & Cancer Drugs Sales Value Market Share by Country (2027-2032) Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Oncology & Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 74. Sanofi Oncology & Cancer Drugs Product Portfolio Table 75. Sanofi Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Oncology & Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 79. Novartis Oncology & Cancer Drugs Product Portfolio Table 80. Novartis Recent Development Table 81. Roche Company Information Table 82. Roche Business Overview Table 83. Roche Oncology & Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 84. Roche Oncology & Cancer Drugs Product Portfolio Table 85. Roche Recent Development Table 86. Lunan Company Information Table 87. Lunan Business Overview Table 88. Lunan Oncology & Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 89. Lunan Oncology & Cancer Drugs Product Portfolio Table 90. Lunan Recent Development Table 91. Eli Lilly and Company Company Information Table 92. Eli Lilly and Company Business Overview Table 93. Eli Lilly and Company Oncology & Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 94. Eli Lilly and Company Oncology & Cancer Drugs Product Portfolio Table 95. Eli Lilly and Company Recent Development Table 96. GuiZhou YiBai Company Information Table 97. GuiZhou YiBai Business Overview Table 98. GuiZhou YiBai Oncology & Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 99. GuiZhou YiBai Oncology & Cancer Drugs Product Portfolio Table 100. GuiZhou YiBai Recent Development Table 101. AstraZeneca Company Information Table 102. AstraZeneca Business Overview Table 103. AstraZeneca Oncology & Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 104. AstraZeneca Oncology & Cancer Drugs Product Portfolio Table 105. AstraZeneca Recent Development Table 106. QILU Company Information Table 107. QILU Business Overview Table 108. QILU Oncology & Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 109. QILU Oncology & Cancer Drugs Product Portfolio Table 110. QILU Recent Development Table 111. LUYE Company Information Table 112. LUYE Business Overview Table 113. LUYE Oncology & Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 114. LUYE Oncology & Cancer Drugs Product Portfolio Table 115. LUYE Recent Development Table 116. HENGRUI Company Information Table 117. HENGRUI Business Overview Table 118. HENGRUI Oncology & Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 119. HENGRUI Oncology & Cancer Drugs Product Portfolio Table 120. HENGRUI Recent Development Table 121. HANSOH Company Information Table 122. HANSOH Business Overview Table 123. HANSOH Oncology & Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 124. HANSOH Oncology & Cancer Drugs Product Portfolio Table 125. HANSOH Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Oncology & Cancer Drugs Distributors List Table 129. Oncology & Cancer Drugs Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Oncology & Cancer Drugs Product Image Figure 2. Global Oncology & Cancer Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology & Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Oncology & Cancer Drugs Sales (2021-2032) & (k tons) Figure 5. Global Oncology & Cancer Drugs Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Oncology & Cancer Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Platinum-based drugs Image Figure 10. Hormone Image Figure 11. Antimetabolite Image Figure 12. Alkaloid drugs Image Figure 13. Targeted drug Image Figure 14. Other Image Figure 15. Global Oncology & Cancer Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 16. Global Oncology & Cancer Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Oncology & Cancer Drugs Sales Volume Share by Type (2021-2032) Figure 18. Global Oncology & Cancer Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Oncology & Cancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Oncology & Cancer Drugs Sales Value Share by Type (2021-2032) Figure 21. Blood Cancer Image Figure 22. Gastrointestinal Cancer Image Figure 23. Breast Cancer Image Figure 24. Prostate Cancer Image Figure 25. Respiratory/Lung Cancer Image Figure 26. Other Image Figure 27. Global Oncology & Cancer Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 28. Global Oncology & Cancer Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 29. Global Oncology & Cancer Drugs Sales Volume Share by Application (2021-2032) Figure 30. Global Oncology & Cancer Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Oncology & Cancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 32. Global Oncology & Cancer Drugs Sales Value Share by Application (2021-2032) Figure 33. Global Oncology & Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 34. Global Oncology & Cancer Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 35. Global Oncology & Cancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 36. Global Oncology & Cancer Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 37. North America Oncology & Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. North America Oncology & Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Europe Oncology & Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Europe Oncology & Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Asia-Pacific Oncology & Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. Asia-Pacific Oncology & Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. South America Oncology & Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 44. South America Oncology & Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 45. Middle East & Africa Oncology & Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 46. Middle East & Africa Oncology & Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 47. USA Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. USA Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. USA Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Canada Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Canada Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Canada Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Mexico Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Mexico Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Mexico Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Germany Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Germany Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Germany Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. France Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. France Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. France Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. U.K. Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. U.K. Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. U.K. Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Italy Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Italy Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Italy Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Spain Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Spain Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Spain Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Russia Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Russia Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Russia Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Netherlands Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Netherlands Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Netherlands Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Nordic Countries Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Nordic Countries Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Nordic Countries Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. China Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. China Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. China Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Japan Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Japan Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Japan Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. South Korea Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. South Korea Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. South Korea Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. India Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. India Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. India Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Australia Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Australia Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Australia Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Southeast Asia Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Southeast Asia Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Southeast Asia Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Brazil Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Brazil Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Brazil Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Argentina Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Argentina Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Argentina Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Chile Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Chile Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Chile Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Colombia Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Colombia Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Colombia Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Peru Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Peru Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Peru Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Saudi Arabia Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Saudi Arabia Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Israel Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Israel Arabia Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Israel Arabia Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. UAE Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. UAE Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. UAE Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Turkey Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Turkey Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Turkey Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Iran Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Iran Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Iran Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Egypt Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 129. Egypt Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 130. Egypt Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 131. Oncology & Cancer Drugs Value Chain Figure 132. Manufacturing Cost Structure Figure 133. Oncology & Cancer Drugs Sales Mode & Process Figure 134. Direct Comparison with Distribution Share Figure 135. Distributors Profiles Figure 136. Years Considered Figure 137. Research Process Figure 138. Key Executives Interviewed

Scope & coverage.

Types
  • Platinum-based drugs
  • Hormone
  • Antimetabolite
  • Alkaloid drugs
  • Targeted drug
  • Other
Applications
  • Blood Cancer
  • Gastrointestinal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Respiratory/Lung Cancer
  • Other
Companies covered
  • Sanofi
  • Novartis
  • Roche
  • Lunan
  • Eli Lilly and Company
  • GuiZhou YiBai
  • AstraZeneca
  • QILU
  • LUYE
  • HENGRUI
  • HANSOH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oncology & Cancer Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Oncology & Cancer Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Oncology & Cancer Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Oncology & Cancer Drugs Market Dynamics
  1. 2.1 Oncology & Cancer Drugs Industry Trends
  2. 2.2 Oncology & Cancer Drugs Industry Drivers
  3. 2.3 Oncology & Cancer Drugs Industry Opportunities and Challenges
  4. 2.4 Oncology & Cancer Drugs Industry Restraints
3 Oncology & Cancer Drugs Market by Company
  1. 3.1 Global Oncology & Cancer Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Oncology & Cancer Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Oncology & Cancer Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Oncology & Cancer Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Oncology & Cancer Drugs Company Ranking (2024-2026)
  6. 3.6 Global Oncology & Cancer Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Oncology & Cancer Drugs Company Product Type and Application
  8. 3.8 Global Oncology & Cancer Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Oncology & Cancer Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Oncology & Cancer Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Oncology & Cancer Drugs Market by Type
  1. 4.1 Oncology & Cancer Drugs Type Introduction
  2. 4.1.1 Platinum-based drugs
  3. 4.1.2 Hormone
  4. 4.1.3 Antimetabolite
  5. 4.1.4 Alkaloid drugs
  6. 4.1.5 Targeted drug
  7. 4.1.6 Other
  8. 4.2 Global Oncology & Cancer Drugs Sales Volume by Type
  9. 4.2.1 Global Oncology & Cancer Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Oncology & Cancer Drugs Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Oncology & Cancer Drugs Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Oncology & Cancer Drugs Sales Value by Type
  13. 4.3.1 Global Oncology & Cancer Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Oncology & Cancer Drugs Sales Value by Type (2021-2032)
  15. 4.3.3 Global Oncology & Cancer Drugs Sales Value Share by Type (2021-2032)
5 Oncology & Cancer Drugs Market by Application
  1. 5.1 Oncology & Cancer Drugs Application Introduction
  2. 5.1.1 Blood Cancer
  3. 5.1.2 Gastrointestinal Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Prostate Cancer
  6. 5.1.5 Respiratory/Lung Cancer
  7. 5.1.6 Other
  8. 5.2 Global Oncology & Cancer Drugs Sales Volume by Application
  9. 5.2.1 Global Oncology & Cancer Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Oncology & Cancer Drugs Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Oncology & Cancer Drugs Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Oncology & Cancer Drugs Sales Value by Application
  13. 5.3.1 Global Oncology & Cancer Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Oncology & Cancer Drugs Sales Value by Application (2021-2032)
  15. 5.3.3 Global Oncology & Cancer Drugs Sales Value Share by Application (2021-2032)
6 Oncology & Cancer Drugs Regional Sales and Value Analysis
  1. 6.1 Global Oncology & Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oncology & Cancer Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Oncology & Cancer Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Oncology & Cancer Drugs Sales by Region (2027-2032)
  5. 6.3 Global Oncology & Cancer Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Oncology & Cancer Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Oncology & Cancer Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Oncology & Cancer Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Oncology & Cancer Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Oncology & Cancer Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Oncology & Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Oncology & Cancer Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Oncology & Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Oncology & Cancer Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Oncology & Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Oncology & Cancer Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Oncology & Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Oncology & Cancer Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Oncology & Cancer Drugs Sales Value Share by Country, 2025 VS 2032
7 Oncology & Cancer Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Oncology & Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oncology & Cancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Oncology & Cancer Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Oncology & Cancer Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Oncology & Cancer Drugs Sales by Country (2027-2032)
  6. 7.4 Global Oncology & Cancer Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Oncology & Cancer Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Oncology & Cancer Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Oncology & Cancer Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Oncology & Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Oncology & Cancer Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Oncology & Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Oncology & Cancer Drugs Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Oncology & Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Oncology & Cancer Drugs Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Oncology & Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Roche Oncology & Cancer Drugs Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Lunan
  20. 8.4.1 Lunan Company Information
  21. 8.4.2 Lunan Business Overview
  22. 8.4.3 Lunan Oncology & Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Lunan Oncology & Cancer Drugs Product Portfolio
  24. 8.4.5 Lunan Recent Developments
  25. 8.5 Eli Lilly and Company
  26. 8.5.1 Eli Lilly and Company Company Information
  27. 8.5.2 Eli Lilly and Company Business Overview
  28. 8.5.3 Eli Lilly and Company Oncology & Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly and Company Oncology & Cancer Drugs Product Portfolio
  30. 8.5.5 Eli Lilly and Company Recent Developments
  31. 8.6 GuiZhou YiBai
  32. 8.6.1 GuiZhou YiBai Company Information
  33. 8.6.2 GuiZhou YiBai Business Overview
  34. 8.6.3 GuiZhou YiBai Oncology & Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GuiZhou YiBai Oncology & Cancer Drugs Product Portfolio
  36. 8.6.5 GuiZhou YiBai Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Oncology & Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Oncology & Cancer Drugs Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 QILU
  44. 8.8.1 QILU Company Information
  45. 8.8.2 QILU Business Overview
  46. 8.8.3 QILU Oncology & Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 QILU Oncology & Cancer Drugs Product Portfolio
  48. 8.8.5 QILU Recent Developments
  49. 8.9 LUYE
  50. 8.9.1 LUYE Company Information
  51. 8.9.2 LUYE Business Overview
  52. 8.9.3 LUYE Oncology & Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 LUYE Oncology & Cancer Drugs Product Portfolio
  54. 8.9.5 LUYE Recent Developments
  55. 8.10 HENGRUI
  56. 8.10.1 HENGRUI Company Information
  57. 8.10.2 HENGRUI Business Overview
  58. 8.10.3 HENGRUI Oncology & Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 HENGRUI Oncology & Cancer Drugs Product Portfolio
  60. 8.10.5 HENGRUI Recent Developments
  61. 8.11 HANSOH
  62. 8.11.1 HANSOH Company Information
  63. 8.11.2 HANSOH Business Overview
  64. 8.11.3 HANSOH Oncology & Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 HANSOH Oncology & Cancer Drugs Product Portfolio
  66. 8.11.5 HANSOH Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oncology & Cancer Drugs Value Chain Analysis
  2. 9.1.1 Oncology & Cancer Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oncology & Cancer Drugs Sales Mode & Process
  6. 9.2 Oncology & Cancer Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oncology & Cancer Drugs Distributors
  9. 9.2.3 Oncology & Cancer Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst